Cargando…

Author Correction: A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Detalles Bibliográficos
Autores principales:	Xie, Xuping, Muruato, Antonio E., Zhang, Xianwen, Lokugamage, Kumari G., Fontes-Garfias, Camila R., Zou, Jing, Liu, Jianying, Ren, Ping, Balakrishnan, Mini, Cihlar, Tomas, Tseng, Chien-Te K., Makino, Shinji, Menachery, Vineet D., Bilello, John P., Shi, Pei-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216087/ https://www.ncbi.nlm.nih.gov/pubmed/34155200 http://dx.doi.org/10.1038/s41467-021-24300-8

Ejemplares similares

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
por: Xie, Xuping, et al.
Publicado: (2020)

Author Correction: A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
por: Muruato, Antonio E., et al.
Publicado: (2021)

Author Correction: Spike mutation D614G alters SARS-CoV-2 fitness
por: Plante, Jessica A., et al.
Publicado: (2021)

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility
por: Shi, Pei-Yong, et al.
Publicado: (2020)

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility
por: Plante, Jessica A., et al.
Publicado: (2020)

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
por: Muruato, Antonio E., et al.
Publicado: (2020)

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
por: Muruato, Antonio E., et al.
Publicado: (2020)

Evaluation of a SARS-CoV-2 lateral flow assay using the plaque reduction neutralization test
por: Xie, Xuping, et al.
Publicado: (2021)

An Infectious cDNA Clone of SARS-CoV-2
por: Xie, Xuping, et al.
Publicado: (2020)

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera
por: Xie, Xuping, et al.
Publicado: (2021)

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
por: Shi, Pei-Yong, et al.
Publicado: (2021)

Author Correction: Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
por: Ku, Zhiqiang, et al.
Publicado: (2021)

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
por: Xie, Xuping, et al.
Publicado: (2021)

Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology
por: Jeremiah, Sundararaj Stanleyraj, et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

A novel nanoluciferase transgenic reporter to measure proteinuria in zebrafish
por: Naylor, Richard W., et al.
Publicado: (2022)

Construction, Characterization and Application of Recombinant Porcine Deltacoronavirus Expressing Nanoluciferase
por: Fang, Puxian, et al.
Publicado: (2021)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

A nanoluciferase biosensor to investigate endogenous chemokine secretion and receptor binding
por: White, Carl W., et al.
Publicado: (2020)

Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples
por: Meyrath, Max, et al.
Publicado: (2022)

Correction for Zhou et al., “Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections”
por: Zou, Jing, et al.
Publicado: (2022)

Coronavirus nonstructural protein 1: Common and distinct functions in the regulation of host and viral gene expression
por: Narayanan, Krishna, et al.
Publicado: (2015)

Nanoluciferase Reporter Mycobacteriophage for Sensitive and Rapid Detection of Mycobacterium tuberculosis Drug Susceptibility
por: Jain, Paras, et al.
Publicado: (2020)

Nanoluciferase Reporter Zika Viruses as Tools for Assessing Infection Kinetics and Antibody Potency
por: Xu, Yanqun, et al.
Publicado: (2023)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
por: Zou, Jing, et al.
Publicado: (2021)

A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein
por: Kamitani, Wataru, et al.
Publicado: (2009)

Interplay between coronavirus, a cytoplasmic RNA virus, and nonsense-mediated mRNA decay pathway
por: Wada, Masami, et al.
Publicado: (2018)

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
por: Liu, Yang, et al.
Publicado: (2022)

Publisher Correction: A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
por: Liu, Yang, et al.
Publicado: (2022)

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
por: Liu, Yang, et al.
Publicado: (2022)

Author Correction: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
por: Menachery, Vineet D., et al.
Publicado: (2020)

Author Correction: Delayed production of neutralizing antibodies correlates with fatal COVID-19
por: Lucas, Carolina, et al.
Publicado: (2021)

Author Correction: The first observation of osmotically neutral sodium accumulation in the myocardial interstitium
por: Artyukov, I., et al.
Publicado: (2021)

A novel nanoluciferase-based system to monitor Trypanosoma cruzi infection in mice by bioluminescence imaging
por: Silberstein, Erica, et al.
Publicado: (2018)

CRISPR-Mediated Protein Tagging with Nanoluciferase to Investigate Native Chemokine Receptor Function and Conformational Changes
por: White, Carl W., et al.
Publicado: (2020)

Nanobody-Nanoluciferase Fusion Protein-Enabled Immunoassay for Ochratoxin A in Coffee with Enhanced Specificity and Sensitivity
por: Bao, Kunlu, et al.
Publicado: (2022)

The N501Y spike substitution enhances SARS-CoV-2 transmission
por: Liu, Yang, et al.
Publicado: (2021)

Author Correction: Pathway to a land-neutral expansion of Brazilian renewable fuel production
por: Ramirez Camargo, Luis, et al.
Publicado: (2022)

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.
por: Lokugamage, Kumari G., et al.
Publicado: (2020)

Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
por: Lokugamage, Kumari G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_idb9g2acn748dt2sirhcdf91q7